What Galena Biopharma Inc. (NASDAQ:GALE) Presented At SITC Conference?
A pharmaceutical company engaged in the research and development of targeted oncology treatments, Galena Biopharma Inc. (NASDAQ:GALE) recently announced to have made a poster presentation at the SITC (Society for Immunotherapy of Cancer) Conference 2013 held at National Harbor, Maryland during November 7-10, 2013. The company presented findings of its Phase I trial related to FBP (Folate Binding Protein) which is a peptide based immunotherapy for preventing recurrences in high-risk endometrial and ovarian cancer patients in combination with GM – CSF (Granulocyte Macrophage Colony Stimulating Factor).
Galena Biopharma Inc. (NASDAQ:GALE) presented the poster titled ‘Phase 1 Trial Results of a Folate Receptor Alpha-directed Cancer Vaccine (E39) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence’ demonstrated the evidence of FBP vaccine being safe and immunogenic. During the trial, the optimal dose for FBP vaccine was determined to be 500 mcg of peptide in combination with 250 mcg GM – CSF. The vaccine was well tolerated with majority of local and systemic toxicities. Local skin reaction plateaued after third injection but was increasing from first to third injections.
The President and Chief Executive Officer of Galena Biopharma Inc. (NASDAQ:GALE), Mark J. Ahn expressed the encouragement with initial Phase-I results of FBP vaccine and mentioned that the company will pursue its plan to initiate Phase-IIa component by year end.
Dr. Erika J. Schneble, who presented the results at the SITC conference on behalf of Galena Biopharma Inc. (NASDAQ:GALE) explained, “New approaches are needed for ovarian and endometrial cancer patients who face a high risk of disease recurrence. The initial results from the Phase 1 trial show that the FBP vaccine may be a potential cancer immunotherapy treatment to prevent recurrence in these high risk patient populations.”
In a related advancement, Peregrine Pharmaceuticals (NASDAQ:PPHM) also presented pre-clinical animal model data in SITC Conference 2013 for its PS (Phosphatidyl-Serine) targeting antibody bavituximab. The company reported enhanced anti-tumor activity in melanoma when combined with FDA approved anti-CTLA4 antibody immunotherapy.